Barclays analyst Carter Gould lowered the firm’s price target on Neurocrine to $131 from $136 and keeps an Overweight rating on the shares post the Q4 results. The analyst says operating costs and taxes growth overshadow the setup for Ingrezza beat and raises over 2023.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NBIX:
- Neurocrine sees FY23 INGREZZA net product sales $1.67B-$1.77B
- Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023
- Neurocrine reports Q4 non-GAAP EPS $1.24, consensus $1.14
- Neurocrine upgraded to Overweight from Equal Weight at Morgan Stanley
- Xenon Pharmaceuticals outlines key milestone opportunities for 2023